Vertex Pharmaceuticals (VRTX) Non-Current Debt (2009 - 2016)

Vertex Pharmaceuticals has reported Non-Current Debt for 5 years, with the latest figure at $74.9 million in Q2 2016.

• For the quarter ending Q2 2016, Non-Current Debt fell 70.26% year-over-year to $74.9 million; the trailing twelve-month figure through Jun 2016 stood at $74.9 million (down 70.26% YoY), and the FY2015 full-year result was $223.9 million, down 20.21% from the prior year.
• Non-Current Debt for Q2 2016 stood at $74.9 million, down from $149.6 million in the prior quarter.
• The five-year high for Non-Current Debt was $294.8 million in Q3 2015, with the low at $74.9 million in Q2 2016.
• Average Non-Current Debt over 3 years is $229.6 million, with a median of $259.1 million recorded in 2015.
• Year-over-year, Non-Current Debt rose 0.03% in 2015 and tumbled 70.26% in 2016.
• Tracing VRTX's Non-Current Debt over 3 years: stood at $280.6 million in 2014, then decreased by 20.21% to $223.9 million in 2015, then plunged by 66.53% to $74.9 million in 2016.
• The last three Non-Current Debt figures came in at $74.9 million (Q2 2016), $149.6 million (Q1 2016), and $223.9 million (Q4 2015), per Business Quant data.

Peer Comparison